Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 19/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 8/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 18/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6214522 | 0.82 | ADORA2A (0.71) | ADORA2AADORA2BADORA1 | |
| SCHEMBL1782226 | 0.76 | ADORA2A (1.00) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL20784800 | 0.75 | DAO (0.39) | ADORA2AADORA2B | |
| SCHEMBL6859325 | 0.74 | ADORA2A (0.49) | ADORA2AADORA2BADORA1 | |
| SCHEMBL6859410 | 0.73 | ADORA2A (0.51) | ADORA2AADORA2BADORA1 | |
| SCHEMBL3656439 | 0.70 | ADORA2A (0.42) | ADORA2AADORA1 | |
| SCHEMBL3655720 | 0.68 | ADORA2A (0.41) | ADORA2AADORA1 | |
| SCHEMBL11854057 | 0.68 | ALOX15 (0.51) | — | |
| SCHEMBL20785461 | 0.68 | GLP1R (0.44) | — | |
| SCHEMBL20784412 | 0.68 | CNR1 (0.36) | ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028097-B2 | Thienopyrimidine compounds | VERNALIS (R&D) LIMITED (GB) | 2021-06-08 | — | — | US | disclosed |
| US-11028097-B2 | Thienopyrimidine compounds | VERNALIS (R&D) LIMITED (GB) | 2021-06-08 | — | — | US | disclosed |
| US-20200140455-A1 | Thienopyrimidine Compounds | VERNALIS DEVELOPMENT LIMITED (GB) | 2020-05-07 | — | — | US | disclosed |
| US-20200140455-A1 | Thienopyrimidine Compounds | VERNALIS DEVELOPMENT LIMITED (GB) | 2020-05-07 | — | — | US | disclosed |
| US-10556911-B2 | Thienopyrimidine compounds | VERNALIS (R&D) LTD. (GB) | 2020-02-11 | — | — | US | disclosed |
| US-10556911-B2 | Thienopyrimidine compounds | VERNALIS (R&D) LTD. (GB) | 2020-02-11 | — | — | US | disclosed |
| US-20180162872-A1 | Thienopyrimidine Compounds | VERNALIS DEVELOPMENT LIMITED (GB) | 2018-06-14 | — | — | US | disclosed |
| US-20180162872-A1 | Thienopyrimidine Compounds | VERNALIS DEVELOPMENT LIMITED (GB) | 2018-06-14 | — | — | US | disclosed |
| US-20180162872-A1 | Thienopyrimidine Compounds | VERNALIS DEVELOPMENT LIMITED (GB) | 2018-06-14 | — | — | US | disclosed |
| US-9920066-B2 | Thienopyrimidine compounds | VERNALIS (R&D) LTD. (GB) | 2018-03-20 | — | — | US | disclosed |
| US-20150342953-A1 | Thienopyrimidine Compounds | VERNALIS DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-9120807-B2 | Thienopyrimidine compounds | VERNALIS (R&D) LTD. (GB) | 2015-09-01 | — | — | US | disclosed |
| US-9120807-B2 | Thienopyrimidine compounds | VERNALIS (R&D) LTD. (GB) | 2015-09-01 | — | — | US | disclosed |
| US-9120807-B2 | Thienopyrimidine compounds | VERNALIS (R&D) LTD. (GB) | 2015-09-01 | — | — | US | disclosed |
| US-20110118284-A1 | THIENOPYRIMIDINE COMPOUNDS | VERNALIS (R&D) LTD. (GB) | 2011-05-19 | — | — | US | disclosed |
| US-20110118284-A1 | THIENOPYRIMIDINE COMPOUNDS | VERNALIS (R&D) LTD. (GB) | 2011-05-19 | — | — | US | disclosed |
| US-20110118284-A1 | THIENOPYRIMIDINE COMPOUNDS | VERNALIS (R&D) LTD. (GB) | 2011-05-19 | — | — | US | disclosed |
| EP-2205607-A1 | THIENOPYRIMIDINE COMPOUNDS | Vernalis (R&D) Ltd. (GB) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009037463-A1 | THIENOPYRIMIDINE COMPOUNDS | VERNALIS (R & D) LTD. (GB) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009037463-A1 | THIENOPYRIMIDINE COMPOUNDS | VERNALIS (R & D) LTD. (GB) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162872-A1 | Thienopyrimidine Compounds | ADORA2B, TBXA2R, ADORA2A | ADORA2A 3/4885ADORA2B 1/4885ADORA1 12/4885 |
| US-20110118284-A1 | THIENOPYRIMIDINE COMPOUNDS | ADORA2B, TBXA2R, ADORA2A | ADORA2A 3/4885ADORA2B 1/4885ADORA1 12/4885 |
| US-11028097-B2 | Thienopyrimidine compounds | ADORA2B, TBXA2R, ADORA2A | ADORA2A 3/4885ADORA2B 1/4885ADORA1 12/4885 |
| US-10556911-B2 | Thienopyrimidine compounds | ADORA2B, TBXA2R, ADORA2A | ADORA2A 3/4885ADORA2B 1/4885ADORA1 12/4885 |
| US-20200140455-A1 | Thienopyrimidine Compounds | ADORA2B, TBXA2R, ADORA2A | ADORA2A 3/4885ADORA2B 1/4885ADORA1 12/4885 |
| US-20150342953-A1 | Thienopyrimidine Compounds | ADORA2B, TBXA2R, ADORA2A | ADORA2A 3/4885ADORA2B 1/4885ADORA1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.